Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
Returns on capital
Actuate Therapeutics Inc management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-280.5%
avg -6645.2%
ROIC
-270.1%
avg -1158.9%
ROA
-158.4%
avg -343.9%
Analysis
ROA is currently the strongest return metric at -158.4% versus its period average of -343.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Daniel Schmitt | Chief Executive Officer, President & Director | USD 712.33K | 64 | — | — |
Andrew Mazar | Co-Founder & Chief Operating Officer | USD 552.15K | 64 | — | — |
Paul J. Lytle | Chief Financial Officer | USD 514.43K | 58 | 105.00K | 0.44% |
Alan Kozikowski | Scientific Founder and Advisor | — | 76 | — | — |
Compensation is shown in the reported currency; data updated Jun 17, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Apr 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$1.62M
Net Transaction Value
−$1.62M
Net selling
Most Active
THOMSON TODD S
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jan 5, 26Jan 5, 2026 | THOMSON TODD S Indirect | Sell | $1.6M$1,624,000.00 |
Summary
Insiders reported 0 buys worth $0.00 and 1 sells worth $1.62M over the last 12 months. That adds up to net selling of $1.62M. THOMSON TODD S was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Actuate Therapeutics Inc compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ACTU's management, answered from reported figures.
Who manages ACTU?
Actuate Therapeutics Inc (ACTU) lists 4 active executives. The top listed executive is Alan Kozikowski, Scientific Founder and Advisor.
Are ACTU insiders buying or selling?
Recent insider activity shows net buying of $7.42M.
Continue the stock analysis
Jump to another research area for this company.